共查询到20条相似文献,搜索用时 15 毫秒
1.
Aguilar-Gallardo C Rutledge EC Martínez-Arroyo AM Hidalgo JJ Domingo S Simón C 《Stem cell reviews》2012,8(3):994-1010
Understanding the genetic and molecular mechanisms of ovarian cancer has been the focus of research efforts working toward the greater goal of improving cancer therapy for patients with residual disease after initial treatment with conventional surgery and neoadjuvant chemotherapy. The focus of this review will be centered on new therapeutic strategies based on Cancer Stem Cells studies of chemoresistant subpopulations, the prevention of metastasis, and individualized therapy in order to find the most successful combination of treatments to effectively treat human ovarian cancer. We reviewed recent literature (1993-2011) of novel treatment approaches to ovarian cancer stem cells. As the focus of ovarian cancer investigation has centered on the cancer stem cell model and the complexities that it presents in the development of effective treatments, the future of treating ovarian cancer lies in utilizing individualized treatment systems that include enhancing existing treatments, aiming for novel therapy targets, managing the plasticity of stem cells to induce cellular differentiation, and regulating oncogenic signaling pathways. 相似文献
2.
Vera Gallo Emilia Cirillo Giuliana Giardino Claudio Pignata 《Journal of clinical immunology》2017,37(8):751-758
Since the discovery of FOXN1 deficiency, the human counterpart of the nude mouse, a growing body of evidence investigating the role of FOXN1 in thymus and skin, has been published. FOXN1 has emerged as fundamental for thymus development, function, and homeostasis, representing the master regulator of thymic epithelial and T cell development. In the skin, it also plays a pivotal role in keratinocytes and hair follicle cell differentiation, although the underlying molecular mechanisms still remain to be fully elucidated. The nude severe combined immunodeficiency phenotype is indeed characterized by the clinical hallmarks of athymia with severe T cell immunodeficiency, congenital alopecia, and nail dystrophy. In this review, we summarize recent discoveries in the field and give interesting perspective about new and promising therapeutic approaches for disorders of immune system with athymia. 相似文献
3.
4.
Biology of human immunoglobulin G Fc receptors. 总被引:27,自引:0,他引:27
5.
We constructed a novel physiologically-based pharmacokinetic (PBPK) model for predicting interactions between the neonatal
Fc receptor (FcRn) and anti-carcinoembryonic antigen (CEA) monoclonal antibodies (mAbs) with varying affinity for FcRn. Our
new model, an integration and extension of several previously published models, includes aspects of mAb-FcRn dynamics within
intracellular compartments not represented in previous PBPK models. We added mechanistic structure that details internalization
of class G immunoglobulins by endothelial cells, subsequent FcRn binding, recycling into plasma of FcRn-bound IgG and degradation
of free endosomal IgG. Degradation in liver is explicitly represented along with the FcRn submodel in skin and muscle. A variable
tumor mass submodel is also included, used to estimate the growth of an avascular, necrotic tumor core, providing a more realistic
picture of mAb uptake by tumor. We fitted the new multiscale model to published anti-CEA mAb biodistribution data, i.e. concentration-time
profiles in tumor and various healthy tissues in mice, providing new estimates of mAb-FcRn related kinetic parameters. The
model was further validated by successful prediction of F(ab′)2 mAb fragment biodistribution, providing additional evidence of its potential value in optimizing intact mAb and mAb fragment
dosing for clinical imaging and immunotherapy applications. 相似文献
6.
Schistosoma mansoni masks its surface with adsorbed host proteins including erythrocyte antigens, immunoglobulins, major histocompatibility complex class I, and beta(2)-microglobulin (beta(2)m), presumably as a means of avoiding host immune responses. How this is accomplished has not been explained. To identify surface receptors for host proteins, we biotinylated the tegument of live S. mansoni adults and mechanically transformed schistosomula and then removed the parasite surface with detergent. Incubation of biotinylated schistosome surface extracts with human immunoglobulin G (IgG) Fc-Sepharose resulted in purification of a 97-kDa protein that was subsequently identified as paramyosin (Pmy), using antiserum specific for recombinant Pmy. Fc also bound recombinant S. mansoni Pmy and native S. japonicum Pmy. Antiserum to Pmy decreased the binding of Pmy to Fc-Sepharose, and no proteins bound after removal of Pmy from extracts. Fluoresceinated human Fc bound to the surface, vestigial penetration glands, and nascent oral cavity of mechanically transformed schistosomula, and rabbit anti-Pmy Fab fragments ablated the binding of Fc to the schistosome surface. Pmy coprecipitated with host IgG from parasite surface extracts, indicating that complexes formed on the parasite surface as well as in vitro. Binding of Pmy to Fc was not inhibited by soluble protein A, suggesting that Pmy does not bind to the region between the CH2 and CH3 domains used by many other Fc-binding proteins. beta(2)m did not bind to the schistosome Fc receptor (Pmy), a finding that contradicts reports from earlier workers but did bind to a heteromultimer of labeled schistosomula surface proteins. This is the first report of the molecular identity of a schistosome Fc receptor; moreover it demonstrates an additional aspect of the unusual and multifunctional properties of Pmy from schistosomes and other parasitic flatworms. 相似文献
7.
Neonatal Fc Receptor: From Immunity to Therapeutics 总被引:1,自引:0,他引:1
Kuo TT Baker K Yoshida M Qiao SW Aveson VG Lencer WI Blumberg RS 《Journal of clinical immunology》2010,30(6):777-789
The neonatal Fc receptor (FcRn), also known as the Brambell receptor and encoded by Fcgrt, is a MHC class I like molecule that functions to protect IgG and albumin from catabolism, mediates transport of IgG across
epithelial cells, and is involved in antigen presentation by professional antigen presenting cells. Its function is evident
in early life in the transport of IgG from mother to fetus and neonate for passive immunity and later in the development of
adaptive immunity and other functions throughout life. The unique ability of this receptor to prolong the half-life of IgG
and albumin has guided engineering of novel therapeutics. Here, we aim to summarize the basic understanding of FcRn biology,
its functions in various organs, and the therapeutic design of antibody- and albumin-based therapeutics in light of their
interactions with FcRn. 相似文献
8.
Berent J. Prakken Salvatore Albani Willem van Eden 《European journal of immunology》2007,37(9):2360-2363
Thirty scientists from Japan, USA and Europe met from January 18th to 20th 2007 in a stormy Amsterdam for an expert meeting on translating immune tolerance into novel therapies. The meeting was held in the “Trippenhouse” a 16th century historical building, home of the Royal Netherlands Academy of Arts and Sciences, the host of the meeting. 相似文献
9.
Antoniu SA 《Clinical reviews in allergy & immunology》2011,41(1):114-122
Hereditary angioedema (HAE) is characterized by acute attacks of edema with multiple localizations, the laryngeal angioedema
being the most potentially lethal. In HAE, C1-INH impairments cause episodic increase in kallikrein activity leading to attacks
of angioedema. Several therapies have recently become available to treat or to prevent HAE attacks, and others are under evaluation
for this indication. Plasma-derived C1-INH, bradykinin receptor antagonists (icatibant), kallikrein inhibitors (ecallantide),
or recombinant C1-INH is authorized on the market for HAE attack therapy or prophylaxis. Some of these compounds can be used
exclusively to treat HAE attacks, whereas others can also be used as prophylactic therapies. Such therapies, although not
available worldwide, can improve disease outcome due to their different mechanisms of action. 相似文献
10.
Jochen C. Ulzheimer Sven G. Meuth Stefan Bittner Christoph Kleinschnitz Bernd C. Kieseier Heinz Wiendl 《BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy》2010,24(4):249-274
Multiple sclerosis (MS) continues to be a therapeutic challenge, and much effort is being made to develop new and more effective immune therapies. Particularly in the past decade, neuroimmunologic research has delivered new and highly effective therapeutic options, as seen in the growing number of immunotherapeutic agents and biologics in development. However, numerous promising clinical trials have failed to show efficacy or have had to be halted prematurely because of unexpected adverse events. Some others have shown results that are of unknown significance with regard to a reliable assessment of true efficacy versus safety. For example, studies of the highly innovative monoclonal antibodies that selectively target immunologic effector molecules have not only revealed the impressive efficacy of such treatments, they have also raised serious concerns about the safety profiles of these antibodies. These results add a new dimension to the estimation of risk-benefit ratios regarding acute or long-term adverse effects.Therapeutic approaches that have previously failed in MS have indicated that there are discrepancies between theoretical expectations and practical outcomes of different compounds. Learning from these defeats helps to optimize future study designs and to reduce the risks to patients. This review summarizes trials on MS treatments since 2001 that failed or were interrupted, attempts to analyze the underlying reasons for failure, and discusses the implications for our current view of MS pathogenesis, clinical practice, and design of future studies. In order to maintain clarity, this review focuses on anti-inflammatory therapies and does not include studies on already approved and effective disease-modifying therapies, albeit used in distinct administration routes or under different paradigms. Neuroprotective and alternative treatment strategies are presented elsewhere. 相似文献
11.
Sven G. Meuth Stefan Bittner Jochen C. Ulzheimer Christoph Kleinschnitz Bernd C. Kieseier Professor Heinz Wiendl 《BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy》2010,24(5):317-330
Currently approved multiple sclerosis (MS) therapeutics have a mainly anti-inflammatory mode of action. However, a number of promising clinical trials have been initiated that either focus on neuroprotection or follow completely different treatment strategies. So far, all of these clinical trials have failed to show efficacy or had to be halted prematurely because of unexpected adverse events. Some others show results that are of unknown significance with regard to a reliable assessment of true efficacy versus safety. For example, trials addressing the highly promising sodium channel blockers are under close observation because of potential adverse effects after drug withdrawal. Previously failed therapeutic approaches in MS have indicated that there are discrepancies between the theoretical expectations and practical outcomes of different compounds. Learning from these failures helps to optimize future study designs and to reduce risks to patients. This review summarizes trials on MS treatments since 2001 that failed or were interrupted, attempts to analyze the underlying reasons for failure, and discusses the implications for our current view of MS pathogenesis, clinical practice, and the design of future studies. In order to maintain clarity, this review focuses on neuroprotective and various other treatment strategies. Clinical trials addressing anti-inflammatory research strategies are presented elsewhere. 相似文献
12.
13.
14.
Multiple lines of evidence have revealed a key role for inhibitory Fc gamma receptors class IIb (FcgammaRIIb) as negative modulators of innate and adaptive immune responses. Acquired and genetic factors regulate the expression of FcgammaRIIb receptors and modify their inhibitory potential. Recent advances have highlighted the importance of FcgammaRIIb receptors in influencing the development of cancer and autoimmunity. The association of increased FcgammaRIIb expression with tumor development is believed to operate at effector cell level resulting in inhibition of antitumor cytotoxicity. In autoimmune diseases, FcgammaRIIb receptors play a major role in controlling the amplitude of antibody- and immune complex-mediated reactions. Generally, FcgammaRIIb deficiency is associated with increased susceptibility and severity to organ-specific and systemic autoimmunity. This article discusses the proposed mechanisms for FcgammaRIIb deregulation associated with malignant and autoimmune pathology in animal models and human diseases. 相似文献
15.
16.
17.
18.
Introduction
Knowledge that antibodies of the IgG isotype have remarkably extended persistence in circulation and are able to pass through cell barriers has substantial implications. While it is well established that so-called neonatal Fc receptor, FcRn, acts throughout life to confer these unusual properties, its ramifications on clinical medicine and therapeutic uses are not broadly appreciated. 相似文献19.
Buonaguro L Petrizzo A Tornesello ML Buonaguro FM 《Clinical and Vaccine Immunology : CVI》2011,18(1):23-34
Vaccines represent a strategic successful tool used to prevent or contain diseases with high morbidity and/or mortality. However, while vaccines have proven to be effective in combating pathogenic microorganisms, based on the immune recognition of these foreign antigens, vaccines aimed at inducing effective antitumor activity are still unsatisfactory. Nevertheless, the effectiveness of the two licensed cancer-preventive vaccines targeting tumor-associated viral agents (anti-HBV [hepatitis B virus], to prevent HBV-associated hepatocellular carcinoma, and anti-HPV [human papillomavirus], to prevent HPV-associated cervical carcinoma), along with the recent FDA approval of sipuleucel-T (for the therapeutic treatment of prostate cancer), represents a significant advancement in the field of cancer vaccines and a boost for new studies in the field. Specific active immunotherapies based on anticancer vaccines represent, indeed, a field in continuous evolution and expansion. Significant improvements may result from the selection of the appropriate tumor-specific target antigen (to overcome the peripheral immune tolerance) and/or the development of immunization strategies effective at inducing a protective immune response. This review aims to describe the vast spectrum of tumor antigens and strategies to develop cancer vaccines. 相似文献
20.